Axsome Therapeutics, Inc. (LON:0HKF)
155.62
+2.41 (1.58%)
At close: Dec 24, 2025
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $170.99M USD in the quarter ending September 30, 2025, with 63.22% growth. This brings the company's revenue in the last twelve months to $561.26M, up 65.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$561.26M
Revenue Growth
+65.83%
P/S Ratio
13.61
Revenue / Employee
$821.76K
Employees
683
Market Cap
5.68B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Axsome Therapeutics News
- 23 days ago - Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue? - Nasdaq
- 26 days ago - 2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
- 4 weeks ago - Axsome (AXSM) Q3 2025 Earnings Call Transcript - The Motley Fool
- 5 weeks ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - 2 Monster Stocks in the Making - The Motley Fool
- 7 weeks ago - AXSM Stock Update: Mizuho Raises Price Target, Maintains Outperform Rating | AXSM Stock News - GuruFocus
- 7 weeks ago - Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus